PCSK9 抑制剂在心血管疾病领域外的研究进展
摘要
得了重要进展，还展现出在其他疾病领域的应用潜力。研究表明，PCSK9 抑制剂在代谢疾病、神经系统疾病、免疫性疾病、
肿瘤、感染等领域展现出良好的前景。尽管这些研究取得阶段成就，但面临着许多挑战，如缺乏大规模临床试验的数据支持、
不同疾病模型下的作用机制尚不明确等。本文旨在综述 PCSK9 抑制剂在心血管领域外的研究进展，探讨其潜在的机制与临
床意义，以期为未来的研究方向提供新的视角和思路。
关键词
全文:
PDF参考
[1]CHEN T, LIU N. How safe are proprotein convertase
subtilisinekexin type 9 inhibitors in diabetes? [J]. Curr Opin
Lipidol, 2024, 35(4): 187-94.
[2]CHEN T, WANG Z, XIE J, et al. Efficacy and safety of
PCSK9 inhibitors in patients with diabetes: A systematic review
and meta-analysis [J]. Nutr Metab Cardiovasc Dis, 2023, 33(9):
1647-61.
[3]JEENDUANG N. Circulating PCSK9 concentrations are
increased in postmenopausal women with the metabolic syndrome
[J]. Clin Chim Acta, 2019, 494: 151-6.
[4] 李玲 , 刘莲 , 刘琳 , 等 .TG/HDL-C,PCSK9,LAP 与胰岛
素抵抗的相关性及其预测糖尿病前期进展的价值 [J]. 南昌大
学学报 : 医学版 , 2023, 63(4):48-52.
[5]YANG Y, WANG Y, WANG Y, et al. PCSK9 inhibitor
effectively alleviated cognitive dysfunction in a type 2 diabetes
mellitus rat model [J]. PeerJ, 2024, 12: e17676.
[6]MEHTA A. Managing dyslipidaemia in patients with
chronic kidney disease [J]. Indian Heart J, 2024, 76 Suppl 1(Suppl
1): S90-s2.
[7]XIE W, LI J, DU H, et al. Causal relationship between
PCSK9 inhibitor and autoimmune diseases: a drug target
Mendelian randomization study [J]. Arthritis Res Ther, 2023,
25(1): 148.
[8]ZHAO S S, YIU Z Z N, BARTON A, et al. Association
of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian
Randomization Study [J]. JAMA Dermatol, 2023, 159(3): 275-80.
[9] 李沁瑶 , 胥崟崧 . PCSK9 抑制剂与自身免疫性疾病
之间的关联 : 孟德尔随机化研究 [J]. 今日药学 , 2024, 34 (06):
419-426.
[10]MAHBOOBNIA K, PIRRO M, MARINI E, et al. PCSK9
and cancer: Rethinking the link [J]. Biomed Pharmacother, 2021,
140: 111758.
[11]HSU C Y, ABDULRAHIM M N, MUSTAFA M A, et al.
The multifaceted role of PCSK9 in cancer pathogenesis, tumor
immunity, and immunotherapy [J]. Med Oncol, 2024, 41(8): 202.
[12]LIU X, BAO X, HU M, et al. Inhibition of PCSK9
potentiates immune checkpoint therapy for cancer [J]. Nature,
2020, 588(7839): 693-8.
[13]LIU H. Association between PCSK9 inhibitors and acute
kidney injury: a pharmacovigilance study [J]. Front Pharmacol,
2024, 15: 1353848.
[14] 周吉 , 陈硕 , 温旭智 . 感染性休克患者 PCSK9 水平
及其对预后评估价值的分析 [J]. 中国现代医生 , 2022, 60 (32):
55-59.
[15]MAGNASCO L, SEPULCRI C, ANTONELLO R M, et
al. The Role of PCSK9 in Infectious Diseases [J]. Curr Med Chem,
2022, 29(6): 1000-15.
(4 摘要 Views, 11 PDF Downloads)
Refbacks
- 当前没有refback。